



Toxicological Profile for Beryllium

Draft for Public Comment

January 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures.
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA Section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health
and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, PhD
Associate Director
Agency for Toxic Substances and Disease
Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
January 2022	Draft for public comment released
June 2015	Addenda released
September 2002	Final toxicological profile released
April 1993	Final toxicological profile released
December 1988	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, PhD (Lead)
Franco Scinicariello, MD, MPH
Breanna Alman, MPH

Meghan Lynch, DSc
Mary Juergens, MPH
Hannah Derrick, BS
Kerry Diskin, DSc
Chimeddulam Dalaijamts, PhD

ATSDR, Office of Innovation and
Analytics, Toxicology Section, Atlanta,
GA

Abt Associates, Cambridge, MA

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Health and Safety (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA

PEER REVIEWERS

1. Jamie DeWitt, Ph.D., Brody School of Medicine, East Carolina University
2. Milton D. Rossman, MD, Perelman School of Medicine, Hospital of the University of Pennsylvania
3. David C. Dorman, DVM, PhD, DABVT, DABT, University of Eastern Finland-Kuopio

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

FOREWORD	i
VERSION HISTORY	iii
CONTRIBUTORS & REVIEWERS	iv
CONTENTS.....	v
LIST OF FIGURES	vii
LIST OF TABLES.....	vii
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES.....	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLS).....	8
CHAPTER 2. HEALTH EFFECTS.....	12
2.1 INTRODUCTION	12
2.2 DEATH.....	45
2.3 BODY WEIGHT	51
2.4 RESPIRATORY	52
2.5 CARDIOVASCULAR.....	76
2.6 GASTROINTESTINAL	77
2.7 HEMATOLOGICAL	78
2.8 MUSCULOSKELETAL.....	80
2.9 HEPATIC.....	81
2.10 RENAL	83
2.11 DERMAL.....	85
2.12 OCULAR.....	86
2.13 ENDOCRINE	87
2.14 IMMUNOLOGICAL	88
2.15 NEUROLOGICAL	95
2.16 REPRODUCTIVE	95
2.17 DEVELOPMENTAL.....	96
2.18 OTHER NONCANCER	97
2.19 CANCER	97
2.19.1 Cancer in Humans.....	98
2.19.2 Cancer in Animals.....	115
2.20 GENOTOXICITY.....	117
2.21 MECHANISM OF ACTION	121
2.21.1 Mechanisms of Toxicity Associated with Respiratory Effects.....	123
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	133
3.1 TOXICOKINETICS	133
3.1.1 Absorption	134
3.1.2 Distribution.....	138
3.1.3 Excretion.....	142
3.1.4 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	145
3.1.5 Animal-to-Human Extrapolations.....	145
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	147
3.3 BIOMARKERS OF EXPOSURE AND EFFECT.....	158
3.3.1 Biomarkers of Exposure	158
3.3.2 Biomarkers of Effect.....	161

3.4 INTERACTIONS WITH OTHER CHEMICALS	166
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	168
4.1 CHEMICAL IDENTITY	168
4.2 PHYSICAL AND CHEMICAL PROPERTIES	170
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	174
5.1 OVERVIEW	174
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	176
5.2.1 Production	176
5.2.2 Import/Export	179
5.2.3 Use	179
5.2.4 Disposal	180
5.3 RELEASES TO THE ENVIRONMENT	181
5.3.1 Air	182
5.3.2 Water	185
5.3.3 Soil	186
5.4 ENVIRONMENTAL FATE	187
5.4.1 Transport and Partitioning	187
5.4.2 Transformation and Degradation	189
5.5 LEVELS IN THE ENVIRONMENT	191
5.5.1 Air	192
5.5.2 Sediment and Soil	195
5.5.3 Water	198
5.5.4 Other Media	201
5.6 GENERAL POPULATION EXPOSURE	205
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	207
CHAPTER 6. ADEQUACY OF THE DATABASE	211
6.1 EXISTING INFORMATION ON HEALTH EFFECTS	211
6.2 IDENTIFICATION OF DATA NEEDS	212
6.3 ONGOING STUDIES	225
CHAPTER 7. REGULATIONS AND GUIDELINES	227
CHAPTER 8. REFERENCES	229
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR BERYLLIUM	B-1
APPENDIX C. USER'S GUIDE	C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E. GLOSSARY	E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

Figure 1-1. Health Effects Found in Animals and Humans Following Inhalation Exposure to Beryllium ..	6
Figure 1-2. Health Effects Found in Animals Following Oral Exposure to Beryllium	7
Figure 1-3. Summary of Sensitive Targets of Beryllium – Inhalation.....	9
Figure 1-4. Summary of Sensitive Targets of Beryllium – Oral.....	10
Figure 2-1. Overview of the Number of Studies Examining Beryllium Health Effects	14
Figure 2-2. Levels of Significant Exposure to Beryllium–Inhalation.....	24
Figure 2-3. Levels of Significant Exposure to Beryllium–Oral.....	36
Figure 2-4. Hypothesized Pathway for Cellular Processing of Beryllium-Containing Particles from Phagocytosis to Antigen Presentation.....	125
Figure 2-5. Steps and Genetic Variants in the Development of Beryllium Sensitization, CBD, and More Severe Forms of Disease.....	127
Figure 2-6. Pathogenesis of CBD	132
Figure 5-1. Number of NPL Sites with Beryllium Contamination	174
Figure 6-1. Summary of Existing Health Effects Studies on Beryllium by Route and Endpoint.....	213

LIST OF TABLES

Table 1-1. Provisional Minimal Risk Levels (MRLs) for Beryllium.....	11
Table 2-1. Levels of Significant Exposure to Beryllium–Inhalation	15
Table 2-2. Levels of Significant Exposure to Beryllium–Oral	30
Table 2-3. Levels of Significant Exposure to Beryllium–Dermal	41
Table 2-4. Summary of Epidemiological Studies Evaluating Mortality	49
Table 2-5. Beryllium Sensitization and Chronic Beryllium Disease in Occupationally Exposed Populations.....	56
Table 2-6. Lung Inflammation Severity Scores in Mice Exposed to Beryllium Metal, Beryllium Oxide, or Beryllium Aluminum	94
Table 2-7. Beryllium Facilities Included in Studies Evaluating Cancer Endpoints.....	99
Table 2-8. Summary of Epidemiological Studies Evaluating Cancer Endpoints	100
Table 2-9. Genotoxicity of Beryllium and Its Compounds <i>In Vitro</i>	120
Table 3-1. Percentage of Lung Deposition as a Function of MMAD.....	135
Table 3-2. Hypothetical Calculation of Workday Beryllium Doses: Dermal Versus Inhalation.....	137
Table 3-3. Hypothetical Calculation of Workday Beryllium Doses: Ingestion versus Inhalation.....	138
Table 3-4. Clearance Mechanisms for Less Soluble and Insoluble Forms of Beryllium.....	142
Table 3-5. Histologic Characteristics of Beryllium-induced Disease in Mice and Humans.....	146
Table 3-6. Risk of BeS and CBD by HLA–DPB1 Glu69 Genotype in Beryllium Workers.....	152
Table 3-7. Risk of BeS and CBD by HLA–DPB1 Glu69 Genotype in Former and Current Beryllium Workers.....	153
Table 3-8. Adjusted OR and 95% CI for Significant IL-1A SNPs for Different Genetic Models.....	156
Table 4-1. Chemical Identity of Beryllium and Beryllium Compounds.....	169
Table 4-2. Physical and Chemical Properties of Beryllium and Beryllium Compounds.....	171
Table 5-1. Facilities that Produce, Process, or Use Beryllium.....	178
Table 5-2. Facilities that Produce, Process, or Use Beryllium (and Compounds).....	178
Table 5-3. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium	183

Table 5-4. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium Compounds	184
Table 5-5. Precipitation of Beryllium Compounds in a Neutral (pH 6.5-9.5) Environment.....	190
Table 5-6. Lowest Limit of Detection for Beryllium Based on Standards	191
Table 5-7. Summary of Environmental Levels for Beryllium	191
Table 5-8. Beryllium Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	192
Table 5-9. Percentile Distribution of Annual Mean Beryllium (TSP) Concentrations (ng/m ³) Measured in Ambient Air at Locations Across the United States	193
Table 5-10. Outdoor Air Monitoring Data for Beryllium	194
Table 5-11. Indoor Air Monitoring Data for Beryllium.....	195
Table 5-12. Concentrations of Beryllium in Soil and Sediment	197
Table 5-13. Groundwater Monitoring Data for Beryllium.....	199
Table 5-14. Beryllium Content of Drinking Water	200
Table 5-15. Concentration of Beryllium in Aluminum and Beverage Samples	201
Table 5-16. Beryllium Content of Various Fresh Foods.....	202
Table 5-17. Beryllium Content of Various Fruits and Fruit Juices	203
Table 6-1. Ongoing Studies on Beryllium	226
Table 7-1. Regulations and Guidelines Applicable to Beryllium	227